# Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma

> **NCT07636252** · — · RECRUITING · sponsor: **Sheba Medical Center** · enrollment: 400 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- Malignant Pleural Effusions (Mpe)

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT07636252
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2028-12-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636252, "Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07636252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*